Compass Therapeutics Investor Presentation Deck

CTX-471: Partial Response in a Patient with Small Cell Lung Cancer after progression on atezolizumab/chemo and nivolumab >>> 66 y.o. man with advanced SCLC: Carboplatin/etoposide plus atezolizumab first line; nivolumab second line Multiple metastases: Largest mass (RUL Lung) shown below, ~ 4 cm at baseline → 40% total decline Confirmed and durable PR at Month 24 COMPASS THERAPEUTICS Baseline Month 4 Month 8 31

View entire presentation